Although both rhGh and rhIGF-I have the potential to provide clinical benefit, each also has the potential to produce unwanted side-effects.
Le Roith
D
D
D000818:Animals; D002986:Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000139:chemically induced; D017277:Drug Approval; D004392:Dwarfism / Q000188:drug therapy; D013006:Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000627:therapeutic use*; D051379:Mice
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone